RhumbLine Advisers
LPCN icon

RhumbLine Advisers’s Lipocine LPCN Stock Holding History

RhumbLine Advisers’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-773
Closed -$51K – 2941
2017
Q1 		$51K Buy
773
+36
+5% +$2.33K ﹤0.01% 2822
2016
Q4 		$46K Sell
737
-319
-30% -$20.2K ﹤0.01% 2829
2016
Q3 		$80K Buy
1,056
+29
+3% +$1.8K ﹤0.01% 2829
2016
Q2 		$53K Buy
+1,027
New +$159K ﹤0.01% 2964

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RhumbLine Advisers's LPCN Position: Q2 2017 in Review

RhumbLine Advisers sold out of Lipocine (LPCN) in Q2 2017, closing a stake of 773 shares — an estimated $51K sold.

RhumbLine Advisers first reported a position in LPCN in Q2 2016 and held it in 4 quarters. The position peaked at $80K in Q3 2016. 42 funds tracked by Wall St. Rank hold LPCN as of Q2 2017.

  • RhumbLine Advisers reported no remaining Lipocine position as of Q2 2017 after selling out during the quarter.
  • RhumbLine Advisers sold 773 Lipocine shares in Q2 2017, an estimated $51K.
  • RhumbLine Advisers first reported a position in Lipocine in Q2 2016 and held it in 4 quarters.
  • RhumbLine Advisers's Lipocine position peaked at $80K in Q3 2016.
  • 42 funds tracked by Wall St. Rank held Lipocine as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.